CAS: 74050-20-7; Hydrocortisone

上下游产品

氢化可的松17-丙酸酯 Hydrocortisone 17-Propionate 65980-97-4
醋酸氢化可的松 Hydrocortisone Acetate 50-03-3
氢化可的松 Hydrocortisone 50-23-7

氢化可的松置于吡啶,对甲苯磺酸,溶剂黄146体系中,用 甲醇,N,N-二甲基甲酰胺 作为反应溶剂,化学反应生成 醋丙氢可的松
参考文献:(多)阳离子 λ3-碘介导的仲醇氧化扩环
标题:(多)阳离子 λ3-碘介导的仲醇氧化扩环
摘要:在此,我们报告了一种通过仲醇与(聚)阳离子λ3-碘(n-Hvi)的亲电活化合成中环醚的简化方法.通过新型 2-Ome-吡啶连接的 N-Hvi 的独特反应性,在已建立的 α-消除途径上实现了 Co 键迁移的优异水平选择性.所得的 Hfip-缩醛很容易用一系列亲核试剂衍生化,为后续操作提供了多功能的功能手柄.还证明了这种方法在后期天然产物衍生化中的实用性,为面向多样性的合成和复杂性到多样性(ctd)工作提供了新工具.初期机理研究揭示了醇构象对反应途径的强烈影响,从而为该方法应用于复杂分子合成提供了预测能力.
DOI:10.1002/ejoc.201800118

专利信息

专利号:WO-0112817-A1
优先权日:1999-08-12
标题:Evolution and use of enzymes for combinathorial and medicinal chemistry
发明人：KREBBER CLAUS; DAVIS S CHRISTOPHER; DELCARDAYRE STEPHEN; SELIFONOV SERGEY A; HOWARD RUSSELL
权利人:MAXYGEN INC; LIU LU; KREBBER CLAUS; DAVIS S CHRISTOPHER; DELCARDAYRE STEPHEN; SELIFONOV SERGEY A; HOWARD RUSSELL
摘要:This invention provides libraries of recombinant derivatizing enzymes that are useful for biocatalytic synthesis of derivatives oforganic molecules, including lead compounds for pharmaceutical use. The recombinant derivatizing enzymes catalyze reactions such as modification or replacement of functional groups on the organicmolecules, or addition of chemical moieties onto preexisting functional groups. The use of recombinant enzyme libraries enables one to obtain enzymes that catalyze the formation of organic molecule derivatives that could not otherwise be made using only naturally occurring enzymes.

专利号:US-8697730-B2
优先权日:2007-10-26
标题 :5-lipoxygenase activating protein (FLAP) inhibitor
发明人：REWOLINSKI MELISSA VIRGINIA; SCHAAB KEVIN MURRAY; KING CHRISTOPHER DAVID; STOCK NICHOLAS SIMON
权利人:REWOLINSKI MELISSA VIRGINIA; SCHAAB KEVIN MURRAY; KING CHRISTOPHER DAVID; STOCK NICHOLAS SIMON; PANMIRA PHARMACEUTICALS LLC
摘要:Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

专利号:US-12304912-B2
优先权日:2020-07-28
标 题 :Fused bicyclic RAF inhibitors and methods for use thereof
发明人：BELFIELD ANDREW; JONES CLIFFORD DAVID; MARGATHE JEAN-FRANÇOIS; COLLETTO CHIARA
权利人:JAZZ PHARMACEUTICALS IRELAND LTD
摘要:The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

专利号:CA-3187393-A1
优先权日:2020-07-28
标题:Chiral synthesis of fused bicyclic raf inhibitors

专利号:EP-4188923-A1
优先权日:2020-07-28
标题 :Chiral synthesis of fused bicyclic raf inhibitors

专利号:WO-2022023450-A1
优先权日:2020-07-28
标题:Chiral synthesis of fused bicyclic raf inhibitors